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HISTORICAL TIPS 
The science of “Immunology” originated in the 19th 
century and grass pollens were identified for the 
first time as the likely trigger of seasonal hay fever 
in the 1870s. Skin allergy testing became an 
accepted assessment technique around 1910. 
Immunoglobulin E (IgE) was identified in the 
1960s. The first scholarly report of immunotherapy 
for allergy appeared by Noon1 and Freeman in 1911 
in the medical journal, The Lancet. Clinical 
attempts to determine the best dose and route for 
allergy therapy increased dramatically in the 1920s 
and 1930s.2 The oral route of immunotherapy was 
suggested earlier in 1900 by Curtis3 but, the clinical 
use of sublingual immunotherapy (SLIT) for foods 
was described in 1969 by David Morris.4 SLIT was 
reintroduced in 1970 for inhalant allergens.5 
Although some patients treated for food, pollen, pet 
dander and mold allergy by SLIT appeared to 
improve, the ideal dose, degree of expected 
improvement, and the mechanism of action were 
not established, and few studies were published in 
peer reviewed journals until the 1990s. Generally, 
sufficient research evidence on the effectiveness 
and mechanism of immunotherapy began to 
accumulate in the last 15 years of the 20th century.6 
 
Background 
The prevalence of allergic diseases has steadily 
increased in populations from western and some 
developing countries over the last three decades.7 
Allergic diseases result from an abnormal response 
of the specific immune system generating allergen-
specific immunoglobulin-E (IgE) antibodies. These 
mediate the various symptoms of allergic diseases, 
such as asthma and allergic rhinitis (AR), upon re-
exposure to this allergen.8 
The late introduction of solid foods during the 
1st year of life – that is generally recommended by 
many physicians – is associated with increased risk 
of allergic sensitization to food and inhalant 
allergens at the age of 5 years.9  
Allergic patients who are challenged with an 
allergen to which they are sensitive often display a 
biphasic inflammatory response. This occurs after 
both nasal and bronchial challenges, and a similar 
phenomenon can be seen in the skin after allergen 
testing. An early phase of symptoms develops 
within minutes of challenge and, in some but not all 
patients; a later phase begins several hours later. 
The early phase corresponds with the release of 
various mediators from local tissue mast cells and 
circulating basophils, including histamine, 
prostaglandin D2, kinins, cysteinyl leukotrienes 
(LTC4, D4, and E4), cytokines, and chemokines. 
These mediators can be measured in nasal 
secretions during nasal challenges. Some of the 
mediators stimulate cell recruitment to the area of 
challenge, leading to a secondary influx of 
inflammatory cells, including T lymphocytes, 
eosinophils, and additional basophils. The newly 
arrived cells release specific inflammatory 
mediators that perpetuate the underlying 
inflammation and contribute to persistent allergic 
symptoms.10  
Unlike drug treatments, which mask or 
suppress allergic reactions, allergen-specific 
immunotherapy (SIT) “resets” the immune system 
to prevent these reactions and hence can be termed 
hyposensitization or desensitization therapy. SIT is 
the repeated administration of increasing amounts 
of purified allergen vaccines to allergic individuals 
with the aim of inducing immunologic tolerance. 
So, it is the only immune-modifying and probable 
etiological therapy for allergy.11  
SIT is a highly cost-effective treatment 
strategy which results in an improved quality of 
life, reduction in days off school/work, long-term 
remission of allergic symptoms, reduction of 
severity of asthma, reduction of the need for 
medication and reduction of the chances of new 
sensitizations to allergens developing.12 It is highly 
effective in IgE-mediated diseases as in allergic 
rhino-conjunctivitis and allergic asthma and in 
patients who develop systemic anaphylactic 
reactions to wasp/bee venom.13 In addition, it is 
most effective specifically for pollen, dust, and 
animal dander allergies.14 
After several months of immunotherapy, 
patients undergoing nasal allergen challenge 
demonstrate a significantly blunted early response; 
although complete inhibition is uncommon. The 
late phase reaction is even more effectively 
reduced.15 
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Mechanism of action of SIT 
Allergen-specific immunotherapy induces marked 
increase in “blocking” IgG antibodies and blunts 
the seasonal increases in allergen specific IgE 
concentrations in patients with seasonal pollinosis. 
There is inhibition of the recruitment and activation 
of effector cells including mast cells, eosinophils, 
and basophils in the allergic respiratory mucosa of 
the nose and bronchi. These “effector” mechanisms 
are modified as a consequence of altered T-
lymphocyte responses following high dose allergen 
exposure during immunotherapy.16 There is 
immune deviation from a "Th2-type" response with 
dominant production of interleukin (IL)-4 and IL-5 
in favour of “Th1-type” responses with production 
of interferon gamma and IL-2. Moreover, it was 
found that osteopontin produced by CD14+ cells 
induced IL-12 in antigen presenting cells to activate 
Th1 responses.17 
Immunotherapy also has been shown to induce 
a subset of “T-regulatory” cells with allergen-
specific increases in the production of IL-10 18 and 
transforming growth factor beta (TGF-β).19 These 
cytokines inhibit T responses and avert antibody 
production in favor of IgG4 – especially in bee or 
wasp venom immunotherapy – and, possibly, IgA 
synthesis with downregulation of IgE responses. 
The end result is a global decrease in the secretion 
of Th2 (i.e., IL-4, IL-5, IL-9 and IL-13) and Th1 
cytokines (i.e., IFN-γ and IL-2), and T-cell hyper-
responsiveness. These events are accompanied by 
suppression of allergen-induced T cell-dependent 
late responses in the skin and lung and long term 
disease suppression which is apparent following 
discontinuation.20  
 
Allergen Extracts and Vaccines 
Allergens are substances that are perceived by the 
immune system mistakenly as threats. Most 
allergens are proteins of low molecular weight; 10-
70 kd. Molecules smaller than 10 kd cannot bridge 
adjacent IgE molecules on the surface of mast cells 
or basophils, to activate and induce degranulation 
of these cells, and those larger than 70 kd cannot 
cross mucosal surfaces to reach the antigen-
presenting cells.21  
The historical term allergen extract was 
changed to allergen vaccine to reflect the fact that 
allergen vaccines are used in medicine as immune 
modifiers. So, allergen vaccines are extract 
preparations that are approved by the FDA as 
therapeutic allergens or immune modifiers for 
treatment of allergic diseases. When possible, 
standardized vaccines of known potency and shelf-
life should be used.22 They are provided as aqueous, 
glycerinated, lyophilized or alum-precipitated 
formulations. There are 4 standardized extracts; 
Cat, Dust Mite, Grass and Ragweed. Some of these 
vaccines are standardized regarding the available 
concentration as those extracts for cat hair, cat pelt, 
Dermatophagoides pteronyssinus and farinae, and 
Hymenoptra venoms.23 
Adjuvants used in conjunction with allergen 
extracts may contribute to further improvement in 
SIT immunogenicity and efficacy, and to shortening 
of treatment duration. Conventional adjuvants 
including aluminium hydroxide or calcium 
phosphate are used by most producers. Novel 
generations of adjuvants – derived from cholera 
toxin and Escherichia coli enterotoxin for mucosal 
priming and boosting24 – may direct the immune 
response more specifically toward a Th1 switch or 
toward T-cell tolerance.25  
Recombinant Allergens are considered as 
effective as purified natural allergens or whole 
allergen extracts. If they are folded in their native 
configuration, they might induce the same adverse 
reactions as the usual extracts because they can then 
bind IgE as natural allergens. They were reportedly 
well tolerated in most patients.26 
Hypoallergenic polymerized formulations of 
whole allergen extracts have been developed for 
this reason. They include the so-called allergoid 
preparations. Site-directed mutagenesis of IgE-
binding sites led to the expression of allergens with 
variable, but significantly decreased IgE-binding 
capacity. That is why hypoallergenic recombinant 
allergen fragments may be administered safely to 
hypersensitive patients at a markedly higher 
concentration than SIT with whole allergen extract 
would allow.27 
 
Immunotherapy Protocols  
Conventional Immunotherapy: 
This involves weekly subcutaneous injections for 8-
16 weeks during an updosing phase till reaching a 
maintenance dose; a dose that is, in principle, well 
tolerated by the patient or induces only limited-to-
minimal local or systemic side effects. Once the 
maintenance dose is reached, the injections are 
administered every two to four weeks (some centers 
empirically extend this interval to 6-8 weeks) for a 
period of 3-5 years. In general, the longer the 
treatment and the higher the dose, the greater is the 
therapeutic benefit. In addition, SIT needs to be 
started 2 – 4 months before the start of the allergen 
season in case of seasonal allergies.28 
Cluster Immunotherapy:  
Accelerated schedules involve two to three 
injections administered per treatment day (with an 
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interval of 30 minutes between the injections) in 
weekly intervals. So, the individual maximum dose 
can be reached after 1–4 weeks depending on the 
depot-allergen preparations or chemically modified 
allergen preparations ('allergoids') used.29 Principles 
of accelerated schedules in SCIT have been 
described first by Freeman30 in the thirties (1930) as 
'intensive desensitization'. These schedules have not 
been widely used in Europe and in the USA, likely 
due to safety concerns.31 The first controlled cluster 
protocols were described by Norman et al. in the 
1980s with 11 injections given in 5 treatment days 
and therapy intervals of 3 weeks in between.32 
A large survey by Mellerup et al. with 650 
allergic patients demonstrated a significantly 
reduced rate of adverse events using a cluster 
schedule with depot-allergens compared to a cluster 
protocol with native aqueous extracts.33 
In a recently published trial, allergic children 
sensitized to house dust mites (HDM) were 
randomized to two groups: 20 children were treated 
with a cluster protocol, whereas 10 children were 
randomized to a 'conventional' protocol to reach a 
maintenance dose within 13 weeks. There was no 
significant difference in the incidence of adverse 
events though the time needed for the dose 
increment in the 'cluster group' was more than half 
lower than in the 'conventional group'. During the 
study, significant immunological effects (increase 
of mite-specific IgG and IgG4 levels) were 
observed in the eighth week after the beginning of 
the cluster schedule while they were demonstrated 
in the conventional group not earlier than 12 weeks 
after the beginning of therapy. These data were 
confirmed by blocking CD63 expression as well as 
release of cysteinyl leukotrienes after in-vitro 
basophil stimulation.34  
So, there is an increasing evidence for 
convincing safety profile of cluster protocols with 
both (native) depot allergens and chemically 
modified allergen preparations ('allergoids'). 
Allergoids were also examined in recently 
published cluster studies such as the study of 
Subiza et al. in which they used a grass mixture 
modified by glutaraldehyde. Large local reactions 
were found after 5.1% of all injections, whereas 
systemic reactions were not observed.35  
As an alternative option for the up-dosing 
phase of SCIT, these protocols account for the 
desire of patients to abbreviate the total length of 
SCIT without a higher risk of adverse reactions. 
This issue is of high importance as inconvenience is 
likely the most common reason for not beginning or 
discontinuing the conventional (or 'leisurely') form 
of SCIT.29  
Cost-effectiveness of cluster protocols was 
also an important issue to assess and preliminary 
data suggest that cluster SIT definitely spares lots 
of money per capita as shown by some studies 
concerned with pharmaco-economics.36 
Rush Immunotherapy:   
This involves repeated updosing injections in order 
to achieve maintenance doses within several hours. 
This protocol is applicable to venom sensitive 
patients, although unsuitable for patients with 
inhalant allergies due to marked increase of side 
effects.37 
 
Routes of Immunotherapy 
Subcutaneous Immunotherapy (SCIT): 
Subcutaneous injection immunotherapy is the only 
approved route in the USA and in general, it is the 
only established form of SIT.38 SCIT proved its 
efficacy in the management of allergic rhinitis and 
asthma, even in multi-allergen mixes. It 
demonstrated effective prevention of new 
sensitizations and progression of rhinitis to asthma. 
The effective doses and duration are well 
established and the persistence of efficacy after 
stopping administration was demonstrated in 
several randomized controlled trials.39 All the SIT 
protocols (discussed before) involve this route of 
SIT administration.40 It is to be noted that patients 
must remain under medical observation for 30 
minutes after an immunotherapy injection in case 
an allergic reaction occurs.41  
Sublingual Immunotherapy (SLIT): 
This is administered under the tongue for two 
minutes and then swallowed46. There is convincing 
evidence that the mechanisms of action of SLIT are 
partially similar to those of SCIT. In particular, 
SLIT is capable of inducing the production of IL-10 
from regulatory T cells, thus modifying the balance 
between Th1 and Th2 cells.42 
Confirmation of the clinical efficacy and 
satisfactory safety of SLIT has been achieved in 
several meta-analyses, large randomized controlled 
trials and post-marketing surveys.43  
In respect to the prevention of asthma in 
children with rhinitis, a randomized open 
prospective study in children receiving SLIT or 
drugs only was published in 2004. This trial 
demonstrated that SLIT can reduce significantly the 
onset of asthma over a 3-year period of observation. 
It was reported to be more effective in AR to grass 
pollen, but not to mites.44 
Another large prospective randomized open 
trial, involving more than 200 children treated with 
SLIT or drugs alone for 3 years, demonstrated that 
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SLIT reduced significantly the onset of persistent 
asthma and the onset of new skin sensitizations.45 
Finally, a long-term follow-up of children with 
mite allergy, showed that SLIT – again – reduced 
the onset of asthma, and that this effect was 
maintained for 5 years after discontinuation.46 
Moreover, all the present studies agree that one 
of the advantages of SLIT over SCIT is greater 
safety in children < 5 years.47 
Many years ago; in 1998, the World Health 
Organization concluded that sublingual 
immunotherapy was a viable alternative to the 
injection route and that its use in clinical practice is 
justified28. In addition, recent studies ascertained 
that SLIT has a shorter escalation phase, equal or 
greater efficacy for rhinitis, and an improved safety 
profile.48 
On the other hand, in a recent review of all 
studies on SLIT by the American Academy of 
Allergy, Asthma and Immunology published in 
Journal of Allergy and Clinical Immunology, 35% 
of studies resulted in significant reductions in 
medications and symptom scores but 38% of 
studies found no significant benefit from SLIT. 
When SLIT did work, it was typically less effective 
than with conventional subcutaneous injection 
immunotherapy and sometimes SLIT took two 
years to show significant clinical benefit.49 
It is clear that more information is needed 
concerning the preventive effect of SLIT, although 
the available data are consistent with a preventive 
capacity of the treatment. 
Advantages of SLIT42, 50 
SLIT has favorable effects on several features of 
airway inflammation, as follows: 
1) It decreases bronchial hyper-responsiveness 
2) It is efficient in preventing asthma development 
in children 
3) It is efficient in preventing the occurrence of 
novel sensitizations  
4) Milder adverse events than SCIT and they are 
mainly local in mouth 
5) Compliance is a key factor for success of SLIT 
Disadvantages of SLIT51 
Weaknesses still compromise the development of 
SLIT, as follows:  
 Only rare dose-ranging studies have been 
performed 
 Unclear benefit in polysensitized patients  
 The optimal duration is not definitely 
characterized 
 Patients' selection criteria are largely undefined 
 Partially defined formulation and mode of 
delivery (tablets versus drops) 
 
Oral Immunotherapy 
Researchers at Hopkins Children's center evaluated 
the efficacy and safety of consuming increasingly 
higher doses of the offending food; either milk or 
egg protein, by children with allergies. They 
reported encouraging results although they 
recommended long-term monitoring of studied 
patients and implementation of these trials only by 
a trained pediatric allergist. Children who received 
that kind of immunotherapy had lower blood levels 
of IgE antibodies and even when symptoms did 
occur, they were mild to moderate in the form of 
itching and swelling of the mouth and throat. In 
another study at the same center, they compared 
SLIT – by placing small amounts of milk protein 
under the tongues of allergic children – to oral 
consumption of milk as before. They found that oral 
therapy was slightly more effective than SLIT, but 
the latter was safer with lower risk for severe 
allergic reactions.52 
OIT was not only studied for foods, but it was 
also tried in allergic rhinitis using – for instance – 
either sublingual tablets of grass pollen or enteric 
and microencapsulated preparations of ragweed 
pollen extract.53 
Local Nasal Immunotherapy 
A double-blind randomized multicenter trial for 
assessment of the efficacy and safety of specific 
local nasal immunotherapy (LNIT) in patients with 
allergic rhinitis was done in Italy in the year 2000. 
The researchers identified allergens with the skin 
prick test (SPT) and sensitization threshold dose 
with the specific nasal provocation test, and then 
they started self-administered treatment using 
insufflators. They evaluated the patients after 32 
weeks of treatment subjectively through self-
reported symptoms and objectively by analysis of 
nasal provocation test, nasal resistance by anterior 
rhinomanometry, and mucociliary clearance time. 
They concluded that specific LNIT is effective for 
allergic rhinitis and appears to offer considerable 
advantages over other hyposensitization methods. It 
can be done at home, patient compliance is good, 
and the treatment is safe.54 
Another study was done by Passàli and 
colleagues55 in Italy also underlined the efficacy 
and quickness of LNIT in the treatment of perennial 
allergic rhinitis. In the same year, another group of 
research workers tested the low-dose LNIT in 
children with perennial allergic rhinitis due to 
Dermatophagoides ascertained the ease of use and 
lack of serious side-effects.56  
In a more recent Egyptian study, 1000 patients 
from 6 Egyptian governorates were enrolled for 
assessment of LNIT. The study showed significant 
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improvement of skin tests, blood, nasal and sputum 
eosinophilia, total IgE levels and nasal symptoms. 
The researcher concluded that LNIT is a simplified, 
self-administrable method with high compliance 
being used at home.57  
Novel modes of delivery 
Apart from the conventional subcutaneous or 
sublingual application, there is place for other 
variants, including intradermal injections, 
transdermal applications, nanotechnologies as well 
as the previously mentioned novel mucosal 
strategies (oral and nasal). The mucosal approach is 
probably the domain where needs for improvements 
to the immunotherapeutic formulations are the most 
acute.28  
Another novel route for SIT is the 
intralymphatic immunotherapy (ILIT).58 This 
administers allergens directly into a subcutaneous 
lymph node enhancing the immune responses to 
protein, peptide, and naked DNA vaccines. Animal 
studies demonstrated a more than 10-fold higher 
IgG2 response with 100-fold lower allergen doses 
than SCIT. Human trials suggest better compliance, 
lower doses and shorter duration of treatment.59  
 
Indications of Immunotherapy 
The treatment of allergic diseases is based on 
allergen avoidance, pharmacotherapy, allergen 
immunotherapy, and patient education. Physicians 
should know the local and regional aerobiology and 
be aware of the potential allergens in the patient’s 
indoor and outdoor environments. Only physicians 
trained in allergology can select the clinically 
relevant allergen vaccines for therapy. 
Immunotherapy, when appropriate, should be used 
in combination with other forms of therapy with the 
hope that the patient will become as symptom-free 
as medically possible.22  
So, SIT is indicated in the following conditions: 
 IgE-mediated disease (symptoms on exposure 
to relevant allergen supported by a positive 
SPT/RAST to that allergen)  
 Inability to avoid allergen(s)  
 Inadequacy of drug treatment  
 Limited spectrum of allergies  
 Patients who understand risks and limitations of 
treatment 
 In venom immunotherapy, an absolute 
indication is a history of severe allergic 
systemic reactions with respiratory symptoms, 
cardiovascular symptoms, or both and positive 
diagnostic tests (skin tests, serum-specific IgE, 
or both).22 
Unfortunately, there are no definite criteria for 
the indication of SLIT versus SCIT and no 
consensus on the degree of severity of asthma still 
compatible with SLIT.60 
Immunotherapy for treatment of allergic 
rhinitis/conjunctivitis is indicated:  
(1) when antihistamines and topical drugs 
insufficiently control symptoms, (2) in patients who 
do not wish to receive pharmacotherapy, (3) when 
pharmacotherapy produces undesirable side effects 
(4) when the patient is concerned about long-term 
pharmacologic therapy, and (5) if the season is 
prolonged or polysensitized patients are exposed to 
several subsequent pollen seasons (i.e., tree, grass, 
and weed pollen sensitivity) The risk/benefit ratio 
should be considered in every case. In addition, 
avoidance is the treatment of choice for animal 
dander–induced allergic diseases and SIT is only 
indicated when complete avoidance is difficult.22 
 
Contraindications 
Contraindications for inhalant allergen and venom 
immunotherapy may be absolute or relative. 
Sublingual immunotherapy is contraindicated in 
patients who have systemic diseases of the immune 
system, inflammatory conditions of the oral cavity 
with associated severe symptoms (e.g. oral lichen 
planus with ulcers or severe oral mycosis) or 
individuals with severe and uncontrolled asthma. 
Immunotherapy tablets are also contraindicated in 
individuals who are allergic to any of the addition 
constituents of the tablet.12  
So, SIT is generally contraindicated in the 
following conditions:61 
 Co-existent uncontrolled asthma (within the 
UK, presence of asthma is considered a relative 
contraindication).  
 Patients with other medical/immunological 
disease  
 Small children (less than 5 years)  
 Pregnancy (maintenance injections may be 
continued during pregnancy)  
 Patients unable to comply with the 
immunotherapy protocol  
 Patients on some heart and blood pressure 
medications such as beta-blockers (relative) 
 
How to ensure success?28 
 Full and precise diagnosis of allergic 
sensitivities by a trained allergologist should be 
documented. 
 Patients’ compliance should be optimal. 
 Polysensitized patients usually fail to benefit 
and allergen avoidance is crucial for them. 
However, a recent study in Italy evaluated SLIT 
in a group of polysensitized children with AR 
and/or mild to moderate asthma. The 
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researchers reported significant improvement of 
allergic symptoms and drug use and they 
concluded that polysensitization is not an 
obstacle for prescribing SLIT.62 
 The quality of the allergen extract is a key to 
SCIT success. Non-standardized allergen 
extracts should be, thus, under close scrutiny by 
regulatory authorities.63  
 Exclude intrinsic asthma. 
 Only select patients with mild-to-moderate 
persistent asthma and not with severe 
uncontrolled conditions, as recommended by 
most of the international guidelines.64 
 Patients with a forced expiratory volume in one 
second (FEV1) lower than 70% of predicted 
(under anti-inflammatory systemic or topical 
treatment) should not be eligible for SCIT. 
 Treatment should start 10 – 14 weeks before the 
start of the grass pollen season. This early start 
results in a 34% reduction of rhino-
conjunctivitis symptoms. 
 
Drawbacks of SIT 65 
1. The long duration of treatment. 
2. The unsatisfactory standardization of allergen 
extracts. 
3. A questionable safety level. 
4. Being injectable in its conventional form; 
SCIT. 
 
Side effects of SIT 
The major risk of SIT is anaphylaxis and asthma 
appears to be a significant risk factor for systemic 
reactions. Itching, swelling, and redness at the site 
of injection are almost constant features.66 
Recently, a new classification for systemic 
reactions related to SCIT has been developed by the 
World Allergy Organization (WAO) which uses a 
5-stage grading system and will allow better 
comparisons of systemic reactions between 
different immunotherapy formulations and 
schedules in the future (table 1).67 
Management of side-effects 
In general, local swelling following injections is to 
be expected. No treatment is required other than 
reassurance, although occasional use of an 
antihistamine may be indicated. Some doctors may 
advise the patient to take an antihistamine a few 
hours before each injection to reduce the likelihood 
of local discomfort and other side-effects.28 
Systemic reactions should be recognized and 
treated promptly, according to recommended 
guidelines. In general, mild rhinitis or wheezing 
may be treated by an antihistamine or 
bronchodilator with continued observation. More 
severe reactions, including moderate asthma, 
urticaria, or angio-oedema require intravenous 
hydrocortisone and antihistamine. Adrenaline 0.5 
mg by the intramuscular route is indicated in 
rapidly evolving systemic reactions which do not 
respond to these measures and in all patients where 
there is associated moderate/severe respiratory 
impairment or hypotension. In general, if in doubt, 
give adrenaline which is more effective when 
administered early during a systemic reaction. 
Delayed systemic reactions are almost always mild, 
involving mild urticaria or asthma and respond to 
antihistamines and/or inhaled bronchodilator 
therapy. Afterwards, the dose should be adjusted to 
a safe level. In the case of SLIT, there is no need to 
do a titrated graduated updose and therapy is 
generally started at the usual clinical dose.68 
Side effects can be avoided if: 
 Patients avoid exercising or overheating for a 
few hours before and after the procedure  
 The first sublingual tablet is administrated 
whilst under observation of a medical doctor 
and observed for 30 minutes for any signs of 
serious side effects.68 
Practical Immunotherapy  
 SCIT should only be administered by trained 
persons in specialist clinics and with immediate 
access to adrenaline and other resuscitative 
measures. All patients should be observed in 
the clinic for at least 30 minutes following 
injections. There should be facilities for vaccine 
storage at 4ºC. In general, injections are given 
in the upper outer surface of the arm half way 
between the shoulder and elbow (figure 1) by 
the deep subcutaneous route. A sterile 
technique should be ensured.16  
 At each immunotherapy visit, a record should 
be made of the date, dose, and volume of 
allergen vaccine given. Peak flow should be 
recorded before and after injections and any 
immediate (0-30 minutes) local or systemic 
reactions must be recorded. Moreover, any 
delayed local or systemic reactions following 
the previous injection should be recorded at the 
next visit. The patient should be well, without 
concomitant allergen exposure, suspected viral 
illness or recent immunization. The time 
interval since the last immunotherapy injection, 
any reaction to previous injections and, if 
indicated, premedication with antihistamine 
should also be checked. Dosage reduction 
according to standard guidelines should be 
performed in relation to previous systemic or 
large local reactions, during increased allergen 
exposure and if there is an extended time 
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interval since the previous injection. With the 
use of small hypodermic syringes pain could be 
alleviated.69 
 In a German study published in 2010, Zielen et 
al. showed that adding a mite allergoid (a 
hypoallergenic mite preparation) SCIT to 
pharmacologic treatment (inhaled fluticasone 
propionate) is an effective and safe strategy to 
reduce corticosteroid doses while maintaining 
disease control in children with mite-induced 
allergic asthma.70 On the other hand, some 
researchers observed that the combined 
administration of an inhaled corticosteroid drug 
and allergen extract suppressed the early 
clinical and immunological effects of SIT and 
that vitamin D3 prevented this 'adverse' 
influence of steroids.71  
 Similarly, intervention with montelukast during 
the build-up phase of SIT significantly impairs 
the induction of regulatory T lymphocytes.72  
 
Table (1). WAO Subcutaneous Immunotherapy Systemic Reaction Grading System75. 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Symptom(s)/sign(s) of 




urticaria, flushing, or 








Rhinitis - (e.g., 
sneezing, rhinorrhea, 






Cough perceived to 
originate in the upper 
airway, not the lung, 
larynx, or trachea 
or 
Conjunctival 
Erythema, pruritus or 
tearing 
Other 
Nausea, metallic taste, 
or headache 
Symptom(s)/sign(s) of more 
than 1 organ system present 
or 
Lower respiratory 
Asthma: cough, wheezing, 
shortness of breath (eg, less 
than 40% PEF or FEV1 drop, 










Asthma (eg, 40% PEF 
or FEV1 drop NOT 




Laryngeal, uvula, or 
tongue edema with or 
without stridor 
Lower or upper 
respiratory 
Respiratory failure 





or without loss of 
consciousness 
Death  
 Patients may also have a feeling of impending doom, especially in grades 2, 3, or 4.  
 Children with anaphylaxis seldom convey a sense of impending doom and their behavior changes may be a sign of anaphylaxis, as 
becoming very quiet or irritable and cranky. 
 Scoring includes a suffix that denotes if and when epinephrine is or is not administered in relationship to onset of 
symptom(s)/sign(s) of the SR:a, ≤ 5 minutes; b, >5 minutes-to ≤10 minutes; c: >10 to ≤20 minutes; d:>20 minutes; z, epinephrine 
not administered. 
 The final grade of the reaction will not be determined until the event is over, regardless of the medication administered. The final 
report should include the first symptom(s)/sign(s) and the time of onset after the subcutaneous allergen immunotherapy injection 
and a suffix reflecting if and when epinephrine was or was not administered. e.g. Grade 2a; rhinitis:10 minutes. 
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Efficacy  
SIT is potentially able to target all mucosa-
associated lymphoid tissues affected by abnormal 
hypersensitivity to allergens. It is highly effective in 
seasonal allergic rhinitis, particularly in patients 
with seasonal pollinosis due to grass, tree, and weed 
pollens and patients with a limited spectrum of 
sensitivities.69  
Regarding asthma, specific aspects of its 
pathogenesis may explain the questionable 
effectiveness of SIT compared to its efficacy in 
rhinoconjunctivitis.  The bronchial remodeling of 
upper and lower airways, as a consequence of 
chronic bronchial inflammation, may be a key 
modulator of response. That is why the prognosis of 
immunotherapy in asthma depends on its severity 
and duration, and on the onset of SIT.73 However, 
evaluation of SIT benefit in asthmatic children is 
somehow difficult because asthmatic subjects have 
often been considered in clinical studies as an at 
risk subgroup among rhinitis patients, rather than a 
target group by itself.28  
However, some studies stated that 
immunotherapy is effective in allergic asthma, 
particularly seasonal asthma, whereas it is less 
effective in perennial asthma.69   
A Cochrane meta-analysis on the efficacy of 
SIT on asthma was published online in 2003. A 
total of 75 trials were selected with allergy to house 
dust mites, pollen, animal dander, Cladosporium, 
latex, and multiple allergens. There was a 
significant reduction in asthma symptoms and 
medication and an improvement in bronchial hyper-
reactivity following immunotherapy. The authors 
recognized that lung-function test results were only 
– partially – reported in 16 studies and hence their 
affection by SIT couldn’t be analyzed.74  
The beneficial effect of SIT on the allergy 
march in children is undoubtedly the most 
important feature of this therapeutic approach. In 
clinical trials, one year of treatment resulted in up 
to 75% reduction in symptoms and medication 
requirement for severe hay fever. For bee and wasp 
venom, there was a 90% or more reduction in the 
risk for anaphylaxis if stung.28 
In the largest clinical program ever conducted 
with grass allergen-SIT in Italy, over 2000 adults 
and more than 500 children have been exposed to 
Grazax; tablets for sublingual use. The new product 
proved to be efficacious and safe both in adults and 
children. Interestingly, continued treatment over 2 
years in the case of grass allergy shows progressive 
desensitization with up to 73 % reduction in 
symptomatology and research in children aged from 
5 to 16 years old shows similar effectiveness in the 
treatment of grass allergy as seen in adults.75 
Another study in Turkey ascertained the 
effectiveness of both SLIT and SCIT in 
asthma/rhinitis children sensitized to HDM.76  
 
Long term benefit 
Allergen immunotherapy has been shown, in 
several studies, to maintain long term benefit 
following discontinuation. For example, in one 
double blind placebo-controlled withdrawal study, 
3-4 years grass pollen immunotherapy was shown 
to result in sustained reduction in symptoms and 
rescue medication for at least 3 years after 
discontinuation.28 
Another convincing study on the preventive 
effect of SIT on asthma in children with seasonal 
rhinitis (with or without asthma) is the longitudinal 
Preventive Allergy Treatment (PAT) study; the first 
controlled prospective trial to address the question 
of long term benefit. The authors followed the 
patients for 7 years after the 3-year treatment period 
and they demonstrated the crucial influence of 
starting SIT early in the course of AR in order to 
limit the risk of progression to asthma.77 
 
Safety 
A limitation of the subcutaneous injection route of 
immunotherapy is the risk of potential side effects, 
which include systemic allergic reactions, 
occasional anaphylaxis and, even, fatalities. Risk 
factors for systemic reactions include extremely 
high sensitivity, co-seasonal allergen exposure, a 
history of previous systemic reactions, and, 
importantly, the presence of bronchial asthma.78 
A major analysis of the incidence of adverse events 
in 912 patients between 1977 and 1987 revealed a 
frequency of adverse events of 2.2% with 8.67% of 
these documented as systemic reactions.79 In a 
double-blind, placebo-controlled study on 40 grass 
pollen allergic patients, Walker et al. found 1.31% 
local reactions and 0.42% systemic reactions of all 
injections.80 Moreover, a higher rate of both local 
and systemic reactions was found in the up-dose 
phase (2.5% and 1% of all injections, respectively). 
Another large review of 38 SCIT studies with 
conventional build-up schedules revealed a rate of 
systemic reactions between 0.05 and 3.2% of all 
injections and between 0.8 and 46.7% of allergic 
patients (mean 12.92%)81 
Life-threatening reactions due to SCIT are very 
rare. The German Paul-Erich-Institute (PEI) 
registered an incidence of 0.002–0.0076% in not 
modified allergen preparations and of 0.0005–
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0.01% in modified allergen preparations 
('allergoids') between 1991 and 2000.82  
Regarding SIT in cases of mold allergy, its 
safety and efficacy are not known in children and 
adolescents. A recent study in Poland evaluated 50 
children and adolescents with Alternaria alternata-
induced seasonal AR and/or bronchial asthma using 
a standardized allergen extract in a randomized, 
double-blind, placebo-controlled, 3-year 
prospective study.  They found that the combined 
symptom medication score decreased; not 
significantly except in the years 2 and 3, and 
sensitivity after nasal challenge also decreased 
without serious side effects. The most common side 
effect was edema at the site of injection only in 11 
injections.83  
Venom immunotherapy (VIT) 
Insect VIT is a potent tool for preventing sting 
anaphylaxis. Controlled studies demonstrate that 
immunotherapy with vespid, honey bee and jack 
jumper ant venoms are highly effective. Once 
subjects are receiving maintenance doses of yellow 
jacket or jumper ant venom, the risk of an 
immediate generalized reaction to a sting is 
approximately 5% per sting. Honey bee VIT is less 
effective by that criterion (the risk of a generalized 
reaction is of the order of 20% per sting), but needs 
to be assessed against an adverse natural history 
without immunotherapy. Many of the documented 
"failures" have involved mild systemic reactions. 
Although a statistical assessment of the effect of 
VIT on the risk of death is difficult if not 
impossible, studies in yellow jacket-sensitive 
subjects have shown a marked improvement in 
quality of life.84 
The earliest markers for protective 
mechanisms against allergic reactions in the 
peripheral blood during the build-up phase of VIT 
were studied in Germany by Bussmann et al. and 
they found that tryptophan depletion, ILT3/4-
mediated inhibition, higher IL-10 production as 
well as intracellular cAMP were the best markers.85 
 
In summary, allergen-specific immunotherapy is a 
promising cure for allergic children that have the 
disadvantage of repeated injections; in its 
conventional form. Well designed and adequately 
powered trials in children are still needed to assess 
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